Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACAC Therapy in Coronary Heart Disease
NCT03618108Phase 2Terminated
- Sponsor
- Cadrock Pty Ltd
- Start
- Apr 2018
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of doxycycline, azithromycin and rifabutin in coronary heart disease (CHD) (2 arms), sponsored by Cadrock Pty Ltd. Primary endpoint: Fractional Flow Reserve at 90 days. Started Apr 2018; status: terminated.
02
Drugs
doxycyclineazithromycinrifabutin
03
Conditions
coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT03618108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618108.